NasdaqGM:LGNDPharmaceuticals
Does Ligand’s Royalty-Focused Leadership Shuffle Reveal a New Strategic Inflection Point for LGND?
In March 2026, Ligand Pharmaceuticals expanded its leadership team by appointing healthcare investors Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, while broadening Lauren Hay’s role to Vice President of Portfolio Strategy and Investments to focus on royalty financing and portfolio optimization.
Around the same time, Chief Financial Officer Octavio Espinoza sold 3,057 shares for about US$688,000 under a prearranged 10b5-1 plan, alongside company...